Jongsma MME, Costes LMM, Tindemans I, Cozijnsen MA, et al. Serum immune profiling in pediatric Crohn's disease demonstrates stronger immune modulation with first-line infliximab than conventional therapy and pre-treatment profiles predict clinical response to both treatments. J Crohns Colitis 2023 Mar 19:jjad049. doi: 10.1093.
PMID: 36934327